Patient Guide: A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 19 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT05338775
Status: ACTIVE_NOT_RECRUITING
Condition: Relapsed/ Refractory Multiple Myeloma
Phase: PHASE1

Where You Can Participate

This study is available at 19 locations across the country.

Top locations include:
  • • Denver, Colorado
  • • New York, New York
  • • New York, New York
  • • And 16 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma - Join Clinical Trial NCTNCT05338775

How to Join This Clinical Trial - NCTNCT05338775

Learn how to participate in this PHASE1 trial studying an investigational therapy for Relapsed/ Refractory Multiple Myeloma. Current status: ACTIVE_NOT_RECRUITING.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Relapsed/ Refractory Multiple Myeloma. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Relapsed/ Refractory Multiple Myeloma
Treatment Being Tested
Investigational treatment
Study Phase
PHASE1 - Early safety study
Enrollment Status
ACTIVE_NOT_RECRUITING
Study Identifier
NCTNCT05338775 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 19 locations. Find a study site near you:

Clinical Research Site

Denver, Colorado 80218 - United States

Status: Contact for availability

Clinical Research Site

New York, New York 10011 - United States

Status: Contact for availability

Clinical Research Site

New York, New York 10029 - United States

Status: Contact for availability

Clinical Research Site

New York, New York 10065 - United States

Status: Contact for availability

Clinical Research Site

Winston-Salem, North Carolina 27157 - United States

Status: Contact for availability

Clinical Research Site

Nashville, Tennessee 37203 - United States

Status: Contact for availability

Clinical Research Site

Nashville, Tennessee 37232 - United States

Status: Contact for availability

Clinical Research Site

Montpellier Cedex 5, 34295 - France

Status: Contact for availability

Clinical Research Site

Nantes Cedex 1, 44093 - France

Status: Contact for availability

Clinical Research Site

Poitiers, 86021 - France

Status: Contact for availability

And 9 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this PHASE1 clinical trial for Relapsed/ Refractory Multiple Myeloma:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships